TGFB1 and neoplasm: During early tumorigenesis, TGF-β acts as a tumor suppressor, but in advanced disease stages, it promotes tumor progression through immunosuppression, epithelial–mesenchymal transition (EMT), and neovascularization—collectively referred to as the “TGF-β paradox”.